Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


April 28, 2015 11:11 AM ET

Biotechnology

Company Overview of Eagle Pharmaceuticals Inc.

Company Overview

Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban to treat heparin-induced thrombocytopenia; and Ryanodex injectable suspension for the treatment of malignant hyperthermia. It develops EP-3101, a bendamustine ready to dilute (RTD) liquid and EP-3102, a bendamustine short infusion time RTD liquid for the treatment of chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma;; and EP-4104, a dantrolene for the treatment of exertional heat stroke. The company also develops EP-5101 (pemetrexed) as RTD liquid, whi...

50 Tice Boulevard

Suite 315

Woodcliff Lake, NJ 07677

United States

Founded in 2007

29 Employees

Phone:

201-326-5300

Key Executives for Eagle Pharmaceuticals Inc.

Chief Executive Officer, President and Director
Age: 54
Total Annual Compensation: $449.6K
Chief Financial Officer
Age: 61
Total Annual Compensation: $265.9K
Chief Medical Officer and Head of Research & Development
Age: 55
Total Annual Compensation: $303.8K
Chief Scientific Officer
Age: 55
Total Annual Compensation: $352.4K
Compensation as of Fiscal Year 2014.

Eagle Pharmaceuticals Inc. Key Developments

Teva and Eagle Pharmaceuticals Announce NDA for Bendamustine Rapid Infusion Product Accepted for Filing

Teva Pharmaceutical Industries Ltd. and Eagle Pharmaceuticals Inc. announced that the New Drug Application for a liquid bendamustine hydrochloride (HCl) rapid infusion product has been accepted for filing by the U.S. Food and Drug Administration. This NDA requests FDA approval of the rapid infusion bendamustine HCl product for the treatment of patients with chronic lymphocytic leukemia (CLL) and patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. This product candidate has received Orphan Drug Designations for both CLL and indolent B-cell NHL, and therefore may be eligible for seven years of exclusivity upon approval. The NDA is supported by data from a clinical trial completed in November 2014, which demonstrated that the rapid infusion bendamustine HCl product can be administered in ten minutes in a low-volume, 50 mL admixture.

Eagle Pharmaceuticals Inc. Appoints David M. Pernock as Board of Directors

Eagle Pharmaceuticals Inc. announced that David M. Pernock, an experienced biotechnology and pharmaceutical executive with over 25 years of industry experience, has been appointed to its board of directors effective immediately. Mr. Pernock is chief executive officer and chairman of the board of Fibrocell Science Inc. Prior to Fibrocell, Mr. Pernock held several positions during his 17-year tenure at GlaxoSmithKline, including: senior vice president of Pharmaceuticals, Vaccines (Biologics), Oncology, Acute Care, and HIV Divisions; vice president of marketing, Pharmaceuticals; vice president of sales and marketing, Oncology; vice president of sales; and vice president of managed care. Previously, Mr. Pernock was vice president of marketing Wyeth Pharmaceuticals and Schering-Plough Corporation, and vice president of sales and marketing at Key Pharmaceuticals. In addition to his role as chairman of the board of Fibrocell Science Inc., Mr. Pernock served on the boards of Martek Biosciences Corporation and the Alliance for Regenerative Medicine. Mr. Pernock was elected to fill a vacancy on the board and will serve as a Class I director with a term of office expiring at the company’s 2015 annual meeting of stockholders.

Eagle Pharmaceuticals Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 01:40 PM

Eagle Pharmaceuticals Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 01:40 PM. Venue: Westin Grand Central Hotel, New York, New York, United States. Speakers: David E. Riggs, Chief Financial Officer, Scott L. Tarriff, Chief Executive Officer, President and Director.

Similar Private Companies By Industry

Company Name Region
Advanced BioNutrition Corp. United States
Codagenix, Inc. United States
Gilead Colorado, Inc. United States
NeuroGenetic Pharmaceuticals, Inc. United States
Spectra Stable Isotopes United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Eagle Pharmaceuticals Inc., please visit www.eagleus.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.